Recent Transactions

01-Jun-21
Undisclosed
United States flag
Target: 

VEP Healthcare

United States flag
Acquiror: 
U.S. Acute Care Solutions

Advised VEP Healthcare, a leading, physician-owned provider of clinical management services in emergent and inpatient settings in the United States, on its merger with U.S. Acute Care Solutions

07-May-21
N/A
United States flag
Target: 

MindPath Care Centers

United States flag
Acquiror: 
Community Psychiatry

Advised Community Psychiatry, a leading provider of outpatient behavioral health services with a focus on high-quality clinically-driven care, on its acquisition of MindPath Care Centers, deepening its national presence to more than 350 providers across the US

31-Mar-21
Pending
~$1.1 billion
Colombia flag
Target: 

Procaps Group

United States flag
Acquiror: 
Union Acquisition Corp. II (NASDAQ: LATN)

Advising Procaps Group, a leading global pharmaceutical technology and healthcare company based in Colombia, on its merger with Union Acquisition Corp. II (NASDAQ: LATN), a special purpose acquisition company

26-Feb-21
Undisclosed
United States flag
Target: 

MDLIVE

United States flag
Acquiror: 
Cigna

Advising Cigna on the acquisition of MDLIVE, a virtual care delivery platform, by Evernorth, Cigna’s health services portfolio

09-Feb-21
Undisclosed
United States flag
Target: 

US Acute Care Solutions

United States flag
Acquiror: 
Apollo Hybrid Value Fund

Advising US Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on its recapitalization and buyout of minority partner, Welsh Carson

29-Dec-20
$110 million
United States flag
Target: 

Biogix, Inc.

United Kingdom flag
Acquiror: 
Alliance Pharma plc

Advised Biogix, Inc., a leader in the development, research and distribution of clinically tested menopause and perimenopause supplements in the U.S. under the flagship brand Amberen, on its sale to Alliance Pharma plc

20-Nov-20
Pending
$1.6 billion
Japan flag
Target: 

Kenedix

Japan flag
Acquiror: 
Sumitomo Mitsui Finance and Leasing

Advising Kenedix, one of the largest Japanese independent real estate asset managers, on its acquisition by Sumitomo Mitsui Finance and Leasing, one of the largest Japanese leasing companies

15-Sep-20
$NA
United States flag
Target: 

Surgery Partners’ Anesthesia Services

United States flag
Acquiror: 
NorthStar Anesthesia

Advised Surgery Partners, a leading owner and operator of surgical facilities, on the divestiture of its anesthesia services business to NorthStar Anesthesia   

12-Aug-20
$225 million
United States flag
Target: 

340B Link

United States flag
Acquiror: 
Omnicell

Advising Omnicell, a leading provider of medication management solutions and adherence tools for health systems and pharmacies, on the acquisition of the 340B Link business from Pharmaceutical Strategies Group (PSG)

02-Jul-20
$890 million
Target: 

Brookfield Property Partners L.P.

Acquiror: 
Brookfield Asset Management Inc.

Advised the Special Committee of Brookfield Property Partners L.P., one of the world’s premier commercial real estate companies, on its repurchase of up to $890 million of publicly held units, funded with an equity investment from Brookfield Asset Management and its affiliates

01-Jul-20
$225 million
United Kingdom flag
Target: 

Cello Health plc

United States flag
Acquiror: 
Arsenal Capital Partners

Advised Cello Health, a global healthcare-focused advisory firm, on a recommended cash offer for its entire issued share capital from Arsenal Capital Partners, a specialised private equity firm based in the United States

10-Jun-20
$3.9 billion
Denmark flag
Target: 

Global collaboration agreement with Genmab A/S

United States flag
Acquiror: 
AbbVie, Inc

Advised AbbVie, Inc, an NYSE-listed global biopharmaceutical company, on a broad collaboration with Genmab A/S, a leading Danish-listed biotechnology company, to jointly develop and commercialise three next-generation bispecific antibody programs  

03-Jun-20
$NA
United States flag
Target: 

Cerner RevWorks

United States flag
Acquiror: 
R1 RCM

Advised Cerner Corporation, a leader in healthcare information technology, on its sale of its RevWorks revenue cycle management services business to R1 RCM, a leading provider of technology-enabled RCM services

23-Mar-20
$68 million
Target: 

Abacus Health Products, Inc.

Acquiror: 
Charlotte’s Web Holdings, Inc.

Advised Abacus Health Products, Inc., a leader in over-the-counter (“OTC”) topical products combining active pharmaceutical ingredients with cannabidiol (“CBD”) hemp extract, on its sale to the Charlotte’s Web Holdings, Inc., a market leader in hemp-derived CBD wellness products. 

18-Mar-20
$NA
Japan flag
Target: 

Centrifuge and processing equipment business of Koki Holdings Co., Ltd.

Germany flag
Acquiror: 
Eppendorf AG

Advised Eppendorf AG, a leading family-owned life science company, on the acquisition of the centrifuge and processing equipment business of KKR-owned Koki Holdings Co., Ltd., a manufacturer of power tools and centrifuge and processing equipment 

15-Jan-20
$NA
United States flag
Target: 

OurHealth

United States flag
Acquiror: 
General Atlantic

Advised OurHealth, a provider of onsite and near-site employer-sponsored primary care clinics, on its sale to General Atlantic and merger with Marathon Health

26-Apr-19
$1.0 billion
United States flag
Target: 

T5 Data Centers Strategic Partnership

Canada flag
Acquiror: 
QuadReal

Advised T5 Data Centers, a leading national data center owner and operator, on the creation of a fully integrated platform with QuadReal Property Group to develop, acquire and operate data centers via a $1.0 billion investment from QuadReal

19-Dec-18
$NA
United States flag
Target: 

Pfizer Inc. Consumer Health Business

United Kingdom flag
Acquiror: 
GlaxoSmithKline plc

Advised GlaxoSmithKline plc ("GSK"), the UK listed international pharmaceutical and consumer healthcare company, on the combination of GSK's and Pfizer's Consumer Health businesses to create a world-leading Joint Venture

19-Dec-18
$NA
Australia flag
Target: 

Starpharma Holdings Limited, patented VivaGel BV® product

Italy, USA flags
Acquiror: 
ITF Pharma, US subsidiary of Italfarmaco S.p.A.

Advised Starpharma Holdings Limited on a US licensing agreement of its patented VivaGel BV® product with ITF Pharma, a US subsidiary of Italfarmaco S.p.A., a privately held European specialty pharmaceutical company

30-Nov-18
$NA
United States flag
Target: 

Aisthesis

United States flag
Acquiror: 
NAPA Management Services Corporation

Advised Aisthesis, a portfolio company of Triton Pacific Capital Partners, on its sale to NAPA, a portfolio company of American Securities

15-Aug-18
$3.9 billion
Canada flag
Target: 

Common shares and common share purchase warrants in Canopy Growth

United States flag
Acquiror: 
Constellation Brands

Advised Canopy Growth on a C$5bn investment by Constellation Brands. As consideration for the investment, Constellation received newly issued Canopy common shares and common share purchase warrants

14-May-18
$1.4 billion
United States flag
Target: 

Campbell Global

United States flag
Acquiror: 
CatchMark Timber Trust, Inc.

Advised CatchMark Timber Trust, Inc. on its purchase of 1.1 million acres of East Texas timberlands from Campbell Global

09-Jan-18
$3.1 billion
Canada flag
Target: 

Pure Industrial Real Estate Trust

United States flag
Acquiror: 
Blackstone Property Partners

Advised the Special Committee of the Board of Trustees of Pure Industrial Real Estate Trust ("PIRET"), the largest pure-play industrial REIT in Canada, regarding the acquisition of PIRET by Blackstone Property Partners

20-Apr-17
$4.3 billion
Canada flag
Target: 

Brookfield Canada Office Properties

United States flag
Acquiror: 
Brookfield Property Partners L.P.

Advised the Special Committee of Brookfield Canada Office Properties, Canada’s pre-eminent office real estate investment trust, on its go private transaction with Brookfield Property Partners L.P.

13-Oct-16
$NA
U.S.A., Canada flags
Target: 

Concordia International Corp

flag not available

Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process

Pages

show all